- AU$65.35m
- AU$76.54m
- AU$50.83m
- 52
- 73
- 45
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.03 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.01 | ||
| Price to Tang. Book | 12.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.29 | ||
| EV to EBITDA | 24.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.98% | ||
| Return on Equity | -6.35% | ||
| Operating Margin | 1.76% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 35.74 | 37.76 | 42.41 | 49.72 | 50.83 | 71.4 | 80 | 7.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +61.03 | n/a | n/a | n/a | n/a | +146.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Compumedics Limited is a medical device company, which is involved in the development, manufacture, and commercialization of diagnostics technology for sleep, brain and ultrasonic blood flow monitoring applications. Its geographic segments include Americas, Australia and Asia Pacific, and Europe and the Middle East. It sells all of its product offerings in this region, including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultra-sonic blood-flow systems, supplies and technical service and support. It provides Sleep Diagnostics and Neurology Diagnostics Solutions. Its products include Compumedics Siesta, Compumedics Somfit, Compumedics Somte PSG and others. It offers Brain Research technologies through the Compumedics Neuroscan brand. Compumedics Neuroscan technologies provide solutions for EEG, ERPs, Source Localization and Functional Neuroimaging. It also provides solutions for sleep applications from high definition 4k full PSG to home sleep testing.
Directors
- David Burton CHM (54)
- David Lawson CFO
- Warwick Freeman CTO
- Rob Ferguson GMG
- Kerry Hubick OTH
- Christoph Witte OTH
- Tucson Dunn DRC
- Paul Jensz DRC
- Alan Anderson NED (59)
- Graham Mitchell NID (78)
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- September 30th, 1987
- Public Since
- December 21st, 2000
- No. of Shareholders
- 1,881
- No. of Employees
- 175
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 192,217,894
- Address
- 30-40 Flockhart St, Abbotsford, MELBOURNE, 3067
- Web
- https://www.compumedics.com/
- Phone
- +61 384207300
- Contact
- David Burton
- Auditors
- Nexia Melbourne Audit Pty Ltd
Upcoming Events for CMP
Similar to CMP
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
Atomo Diagnostics
Australian Stock Exchange - SEATS
FAQ
As of Today at 20:02 UTC, shares in Compumedics are trading at AU$0.34. This share price information is delayed by 15 minutes.
Shares in Compumedics last closed at AU$0.34 and the price had moved by +4.62% over the past 365 days. In terms of relative price strength the Compumedics share price has underperformed the ASX All Ordinaries Index by -4.03% over the past year.
The overall consensus recommendation for Compumedics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCompumedics does not currently pay a dividend.
Compumedics does not currently pay a dividend.
Compumedics does not currently pay a dividend.
To buy shares in Compumedics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.34, shares in Compumedics had a market capitalisation of AU$65.35m.
Here are the trading details for Compumedics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CMP
Based on an overall assessment of its quality, value and momentum Compumedics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Compumedics is AU$0.80. That is 135.29% above the last closing price of AU$0.34.
Analysts covering Compumedics currently have a consensus Earnings Per Share (EPS) forecast of AU$0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compumedics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -0.98%.
As of the last closing price of AU$0.34, shares in Compumedics were trading +18.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Compumedics PE ratio based on its reported earnings over the past 12 months is 16.03. The shares last closed at AU$0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Compumedics' management team is headed by:
- David Burton - CHM
- David Lawson - CFO
- Warwick Freeman - CTO
- Rob Ferguson - GMG
- Kerry Hubick - OTH
- Christoph Witte - OTH
- Tucson Dunn - DRC
- Paul Jensz - DRC
- Alan Anderson - NED
- Graham Mitchell - NID